Abstract
Abstract Each chain of the αβ T-cell receptor (TCR) contains a constant (C) region and an antigen-binding variable (V) region. There are two human isoforms of the TCR β chain, TRBC1 and TRBC2, differing slightly in the constant region, and individual αβ T-cells express one isoform or the other. The ratio of TRBC1+ to TRBC2+ αβ T-cells falls within a characteristic range of healthy donors; monoclonal T-cell malignancies skew this ratio dramatically. A monoclonal antibody specific for TRBC1 (clone JOVI.1) is unable to directly identify both TRBC1+ and TRBC2+ T cell malignancies as is done for B cell cancers using k and λ-specific antibodies. Here we characterize clone SAM.2.rMAb, to our knowledge the first monoclonal antibody that selectively binds TRBC2, and demonstrate its use by flow cytometry in combination with JOVI.1 to confirm the mutually exclusive expression of TRBC1 and TRBC2 in T cells, NKT cells, MAIT cells and Treg. This new clone allows direct identification of TRBC2+ cells, is compatible with BD buffers and can be used in phenotyping panels that include TCRαβ and CD3 antibodies. SAM.2.rMAb is thus a valuable flow cytometry reagent to potentially combine with JOVI.1 in building rapid and low-cost research use only immunophenotyping assays for basic and applied research on human T-cell malignancies. For Research Use Only. Not for use in diagnostic or therapeutic procedures. BD is a trademark of Becton, Dickinson and Company or its affiliates. © 2023 BD. All rights reserved.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call